GlassScriptPhysician profile
Mckindra Fletcher
NPI 1467448019
$5,079.27
in general payments reported to CMS, 2019-2025
26 companies · $8.24 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $579 · 2021: $971 · 2022: $1,220 · 2023: $674 · 2024: $606 · 2025: $8.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $764.27 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $742.26 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $569.70 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $501.10 | 2019-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $452.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $317.68 | 2019-2024 | Eliquis |
| Esperion Therapeutics, INC. | $205.46 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $193.36 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.58 | 2021-2022 | |
| Cardiovascular Systems INC. | $156.16 | 2022 | |
| Pfizer INC. | $152.01 | 2019-2024 | |
| Boston Scientific Corporation | $108.13 | 2022 | |
| Alnylam Pharmaceuticals INC. | $95.76 | 2020-2023 | Onpattro |
| Sanofi-Aventis U.S. LLC | $90.77 | 2019 | |
| Edwards Lifesciences Corporation | $89.65 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $80.92 | 2021-2024 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $72.11 | 2021-2022 | |
| Gilead Sciences, INC. | $53.91 | 2019 | |
| Shockwave Medical, INC | $49.24 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Scpharmaceuticals INC. | $46.06 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $37.27 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $33.51 | 2019-2021 | |
| Vifor Pharma, INC. | $23.93 | 2021 | |
| Itamar Medical INC | $22.63 | 2024 | Watchpatone |
| W. L. Gore & Associates, INC. | $22.56 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckindra Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.